These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
172 related items for PubMed ID: 17194595
1. Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists. Chiba J, Iimura S, Yoneda Y, Watanabe T, Muro F, Tsubokawa M, Iigou Y, Satoh A, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N. Bioorg Med Chem; 2007 Feb 15; 15(4):1679-93. PubMed ID: 17194595 [Abstract] [Full Text] [Related]
2. Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist. Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N. Bioorg Med Chem; 2008 Dec 01; 16(23):9991-10000. PubMed ID: 18952443 [Abstract] [Full Text] [Related]
3. A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid. Muro F, Iimura S, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Takayama G, Yokoyama M, Takashi T, Nakayama A, Machinaga N. Bioorg Med Chem; 2009 Feb 01; 17(3):1232-43. PubMed ID: 19124247 [Abstract] [Full Text] [Related]
4. Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist. Chiba J, Machinaga N, Takashi T, Ejima A, Takayama G, Yokoyama M, Nakayama A, Baldwin JJ, McDonald E, Moriarty KJ, Sarko CR, Saionz KW, Swanson R, Hussain Z, Wong A. Bioorg Med Chem Lett; 2005 Jan 03; 15(1):41-5. PubMed ID: 15582407 [Abstract] [Full Text] [Related]
5. Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists. Chiba J, Takayama G, Takashi T, Yokoyama M, Nakayama A, Baldwin JJ, McDonald E, Moriarty KJ, Sarko CR, Saionz KW, Swanson R, Hussain Z, Wong A, Machinaga N. Bioorg Med Chem; 2006 Apr 15; 14(8):2725-46. PubMed ID: 16377201 [Abstract] [Full Text] [Related]
6. Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist. Muro F, Iimura S, Sugimoto Y, Yoneda Y, Chiba J, Watanabe T, Setoguchi M, Iigou Y, Matsumoto K, Satoh A, Takayama G, Taira T, Yokoyama M, Takashi T, Nakayama A, Machinaga N. J Med Chem; 2009 Dec 24; 52(24):7974-92. PubMed ID: 19891440 [Abstract] [Full Text] [Related]
7. Synthetic study of VLA-4/VCAM-1 inhibitors: synthesis and structure-activity relationship of piperazinylphenylalanine derivatives. Saku O, Ohta K, Arai E, Nomoto Y, Miura H, Nakamura H, Fuse E, Nakasato Y. Bioorg Med Chem Lett; 2008 Feb 01; 18(3):1053-7. PubMed ID: 18160288 [Abstract] [Full Text] [Related]
8. Discovery of a novel series of biphenyl benzoic acid derivatives as potent and selective human beta3-adrenergic receptor agonists with good oral bioavailability. Part I. Imanishi M, Tomishima Y, Itou S, Hamashima H, Nakajima Y, Washizuka K, Sakurai M, Matsui S, Imamura E, Ueshima K, Yamamoto T, Yamamoto N, Ishikawa H, Nakano K, Unami N, Hamada K, Matsumura Y, Takamura F, Hattori K. J Med Chem; 2008 Mar 27; 51(6):1925-44. PubMed ID: 18307290 [Abstract] [Full Text] [Related]
9. Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists. Witherington J, Blaney EL, Bordas V, Elliott RL, Gaiba A, Garton N, Green PM, Naylor A, Smith DG, Spalding DJ, Takle AK, Ward RW. Bioorg Med Chem Lett; 2006 Nov 01; 16(21):5538-41. PubMed ID: 16931004 [Abstract] [Full Text] [Related]
10. Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. Salem OI, Frotscher M, Scherer C, Neugebauer A, Biemel K, Streiber M, Maas R, Hartmann RW. J Med Chem; 2006 Jan 26; 49(2):748-59. PubMed ID: 16420060 [Abstract] [Full Text] [Related]
11. Discovery of novel series of benzoic acid derivatives containing biphenyl ether moiety as potent and selective human beta(3)-adrenergic receptor agonists: Part IV. Nakajima Y, Imanishi M, Itou S, Hamashima H, Tomishima Y, Washizuka K, Sakurai M, Matsui S, Imamura E, Ueshima K, Yamamoto T, Yamamoto N, Ishikawa H, Nakano K, Unami N, Hamada K, Hattori K. Bioorg Med Chem Lett; 2008 Sep 15; 18(18):5037-40. PubMed ID: 18752946 [Abstract] [Full Text] [Related]
12. Influence of acid surrogates toward potency of VLA-4 antagonist. Venkatraman S, Lim J, Cramer M, Gardner MF, James J, Alves K, Lingham RB, Mumford RA, Munoz B. Bioorg Med Chem Lett; 2005 Sep 15; 15(18):4053-6. PubMed ID: 16039122 [Abstract] [Full Text] [Related]
13. Imidazopyridines as VLA-4 integrin antagonists. Phillips DJ, Davenport RJ, Demaude TA, Galleway FP, Jones MW, Knerr L, Perry BG, Ratcliffe AJ. Bioorg Med Chem Lett; 2008 Jul 15; 18(14):4146-9. PubMed ID: 18539454 [Abstract] [Full Text] [Related]
14. Design, synthesis, and pharmacological evaluation of glutamate carboxypeptidase II (GCPII) inhibitors based on thioalkylbenzoic acid scaffolds. Stoermer D, Vitharana D, Hin N, Delahanty G, Duvall B, Ferraris DV, Grella BS, Hoover R, Rojas C, Shanholtz MK, Smith KP, Stathis M, Wu Y, Wozniak KM, Slusher BS, Tsukamoto T. J Med Chem; 2012 Jun 28; 55(12):5922-32. PubMed ID: 22642259 [Abstract] [Full Text] [Related]
15. 4-(Pyrrolidinyl)methoxybenzoic acid derivatives as a potent, orally active VLA-4 antagonist. Chiba J, Iimura S, Yoneda Y, Sugimoto Y, Horiuchi T, Muro F, Ochiai Y, Ogasawara T, Tsubokawa M, Iigou Y, Takayama G, Taira T, Takata Y, Yokoyama M, Takashi T, Nakayama A, Machinaga N. Chem Pharm Bull (Tokyo); 2006 Nov 28; 54(11):1515-29. PubMed ID: 17077548 [Abstract] [Full Text] [Related]
16. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4. Okigami H, Takeshita K, Tajimi M, Komura H, Albers M, Lehmann TE, Rölle T, Bacon KB. Eur J Pharmacol; 2007 Mar 22; 559(2-3):202-9. PubMed ID: 17234179 [Abstract] [Full Text] [Related]
17. Discovery of inhibitors of plasminogen activator inhibitor-1: structure-activity study of 5-nitro-2-phenoxybenzoic acid derivatives. Pandya V, Jain M, Chakrabarti G, Soni H, Parmar B, Chaugule B, Patel J, Joshi J, Joshi N, Rath A, Raviya M, Shaikh M, Sairam KV, Patel H, Patel P. Bioorg Med Chem Lett; 2011 Oct 01; 21(19):5701-6. PubMed ID: 21880486 [Abstract] [Full Text] [Related]
18. Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model. Semko CM, Chen L, Dressen DB, Dreyer ML, Dunn W, Farouz FS, Freedman SB, Holsztynska EJ, Jefferies M, Konradi AW, Liao A, Lugar J, Mutter L, Pleiss MA, Quinn KP, Thompson T, Thorsett ED, Vandevert C, Xu YZ, Yednock TA. Bioorg Med Chem Lett; 2011 Mar 15; 21(6):1741-3. PubMed ID: 21316228 [Abstract] [Full Text] [Related]
19. Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4. Lin LS, Lanza TJ, Castonguay LA, Kamenecka T, McCauley E, Van Riper G, Egger LA, Mumford RA, Tong X, MacCoss M, Schmidt JA, Hagmann WK. Bioorg Med Chem Lett; 2004 May 03; 14(9):2331-4. PubMed ID: 15081035 [Abstract] [Full Text] [Related]
20. Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist. Venkatraman S, Lebsack AD, Alves K, Gardner MF, James J, Lingham RB, Maniar S, Mumford RA, Si Q, Stock N, Treonze KM, Wang B, Zunic J, Munoz B. Bioorg Med Chem Lett; 2009 Oct 01; 19(19):5803-6. PubMed ID: 19713111 [Abstract] [Full Text] [Related] Page: [Next] [New Search]